Use of Biologics in the Treatment of Moderate-to-Severe Plantar Psoriasis

Clin Podiatr Med Surg. 2021 Oct;38(4):553-559. doi: 10.1016/j.cpm.2021.06.007.

Abstract

Psoriasis is a common inflammatory disorder with potentially severe systemic and dermatologic consequences. As traditional treatments for this condition fail, biologics are emerging as the next promising therapy for moderate-to-severe cases, especially for the lower extremity. This review examines current research on monoclonal antibodies that target specific cytokines including interleukin-23 (IL-23), IL-12, tumor necrosis factor alpha, and IL-17 involved in pathologic inflammatory processes.

Keywords: Biologics; Cytokine; Inflammatory; Interleukin; Monoclonal antibodies; Psoriasis.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Biological Products* / therapeutic use
  • Humans
  • Interleukin-23
  • Psoriasis* / drug therapy
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal
  • Biological Products
  • Interleukin-23
  • Tumor Necrosis Factor-alpha